Alicia Zhou brings startup bona fides to the nonprofit Cancer Research Institute to promote...
Author - simom
Patient access: How Novartis, Eli Lilly, and other Big Pharmas...
A new report examines the patient reach efforts of 20 of the world’s largest pharma companies in...
What the Fed’s rate cut means for biotech
Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost...
After epilepsy setback, Ovid charges confidently ahead in CNS
A promising epilepsy drug Ovid sold to Takeda recently missed the mark in late-stage trials. But...
Kyverna follows oncology’s CAR-T cell playbook for an...
The pharma company is tackling the “stiff person syndrome” that afflicts Celine Dion in a phase...
Gilead’s CMO to depart next year
Merdad Parsey joined Gilead as its chief medical officer in 2019 and has helped lead the...
Gilead eyes ‘ending the HIV epidemic’ via incremental...
With a long elusive HIV cure ever on the horizon, Gilead’s latest long-acting PrEP study shows...
A new biotech tackling IBD joins a race against Lilly and Gilead...
Ensho Therapeutics just launched but is already generating buzz with its phase 2-ready clinical...
Amylyx’s CEOs on their ALS setback and quest to revamp the...
Co-CEOs Josh Cohen and Justin Klee reflect on what they learned from Relyvrio’s failure and how...
Has pharma emerged from the ‘age of uncertainty’?
An industry reeling from a precarious market is showing signs of stabilizing as the future becomes...